1. Purpose
The standard antenatal check provides the basis for routine screening, assessment, referral and education for women attending the antenatal clinic.
These guidelines are not exhaustive. They are designed to work alongside the antenatal record.
Please also refer to the Antenatal Care Schedule- Routine Low Risk.

2. Definitions
LNMP: Last normal menstrual period.

3. Responsibilities
Midwives, Medical staff and Shared Care GP'/Midwives.

4. Guideline
4.1. Gestation and estimated due date (EDD)
Gestation is recorded at each visit.
Calculate the EDD according to the following:
- **The EDD is according to the LNMP is used if:**
  o The LNMP is reliable (the woman is certain of the first day of LNMP and she has a regular 28 to 35* day cycle)
  o The early dating scan calculates the EDD to be within 5 days of a reliable LNMP due date
- **The EDD according to the Early Dating Ultrasound is used if:**
  o The LNMP is unreliable and/or
  o The early dating scan calculates the EDD outside 5 days of a reliable LNMP due date
  o Ultrasound performed prior to 14 weeks is more accurate for estimating gestation
- **The 19-21 week scan should be used if:**
  o there was no dating scan performed and
  o the LNMP is unreliable and/or
  o the 19-21 week scan calculates the EDD outside 10 days of a reliable LNMP due date*.

*Add 7 days to the EDD when a woman has a regular 35 day cycle.

4.2. Urinalysis
Urine testing for asymptomatic bacteriuria (AB) and chronic renal disease (CRD) to be done at first antenatal visit
- If at any visit a woman reports symptoms of a urinary tract infection, or screening for bacteriuria is indicated, then a MSU for MC&S should be sent to pathology. Contact the team registrar as they may decide to commence antimicrobial agents and/or review the woman before awaiting results. If left untreated, UTIs can lead to pre-term births and low birth weight infants.

Urine testing for proteinuria
The Women’s does not routinely screen low-risk women for proteinuria at each antenatal visit (Level IV evidence).
Please refer to the section headed Blood Pressure for further clarification on testing for proteinuria when indicated.

**Urine testing for glycosuria / screening for diabetes in pregnancy**

Glycosuria is normal in pregnant women.

The Women’s do not screen women routinely for glycosuria at each antenatal visit. If a woman is suspected of having a problem with carbohydrate metabolism, then a Glucose Tolerance Test (GTT) is indicated.

All women will continue to be offered routine screening for gestational diabetes with a Glucose Tolerance Test (GTT) at 26-28 weeks via venepuncture.

Any woman with a history of GDM or immediate family history of diabetes requires a GTT by 16 weeks or as soon as feasible and referred to the diabetic educator for counselling if the GTT is abnormal. If the GTT is negative, repeat the GTT at 26-28 weeks.

**4.3. Blood pressure**

Strategies to avoid and treat light-headedness and fainting that are due to normal physiological changes should be discussed with all pregnant women.

Blood Pressure\(^1\) is monitored at every antenatal visit to detect the following hypertensive disorders:

- Essential hypertension
- Gestational hypertension\(^2\)
- Pre-eclampsia / eclampsia

A woman is hypertensive when:

- Systolic BP is \(\geq 140\) mmHg and/or
- Diastolic BP is \(\geq 90\) mmHg for two or more consecutive occasions over several hours

For women with an upper arm circumference >35cm, use large cuff

1. If hypertensive, wait 15 minutes before repeating BP, following rest.
2. If hypertension persists, perform a dipstick urinalysis as an initial screen for proteinuria.
3. Inquire about fetal movements, general wellbeing, headaches, visual disturbances, epigastric pain and assess for oedema. Record these details in the Pregnancy Record. Notes: 50-80% of normotensive pregnant women experience moderate oedema, usually in the lower limbs but also fingers, face or generalised (change to ref no)
4. Refer all hypertensive women (BP \(\geq 140/90\) and <170/110), with or without symptoms, to the Pregnancy Day Care Centre before 5pm. After hours refer to the Emergency Department assessment clinic or consider admission.
5. The woman’s assessment in the PDCC may include serial blood pressure measurements over four hours, in addition to some of the following: a CTG, AFI, Dopplers, FBE, LFT, urea, creatinine, uric acid, and spot protein creatinine ratio.
6. Depending on outcomes, the staff of the PDCC, Emergency Department assessment clinic and/or the reviewing medical officer will decide with the woman her subsequent care path.
7. It is envisaged that it is a shared responsibility between the assessing area/unit, team doctors and midwives to communicate and follow up the woman’s subsequent care path.

**Note:** If BP \(\geq 170/110\) mmHg, refer immediately to the obstetric registrar on call for admission to Birth Suite for intensive care

- Provide a calm environment and do not leave the woman unattended
- Do not ask the woman to provide a specimen for urinalysis
4.4. Fundal height – symphysis-fundal (S-F) height measurement (singleton, 24+ weeks)

Assess all women at booking and at each visit for the risk of fetal growth restriction (FGR). Refer to Appendix 1 for the Risk Assessment flowchart.

Refer to Appendix 1 for the Risk Assessment flowchart.

Refer women with identified risks (level 2 and 3) to the medical team and document the plan for assessing fetal growth.

Follow a standardised measurement procedure (Appendix 2) and plot the growth on the SF-Height chart MR/1209 from 24 weeks onwards.

Report discrepancies:

- in growth pattern to the medical team and document a plan.
- of ≥ 3cm or more from the gestational age to medical staff and document any actions or plans for care.
- Refer to the guidelines Fetal Growth restriction- Improving the Antenatal Detection and Management of Fetal Growth Restriction for further information.

4.5. Fetal movements

We can expect primigravida women to begin feeling fetal movement from around 20-22 weeks and multigravida woman from around 18-20 weeks. Each woman will experience fetal movements at an amount that is normal for her, i.e. she will get used to the pattern of fetal movements.

In Clinic

1. All women are to be asked about fetal movements at each visit from around 20 weeks and encouraged to report any perceived reduction in fetal movements as soon as possible.

2. Any woman with a perceived reduction in fetal movements after 26-27 weeks, including women approaching term, should be referred immediately to the PDCC (or Emergency Department Assessment Clinic if after 5pm) for CTG assessment.

3. You may or may not detect fetal movements during your palpation, but if so, record in the Pregnancy Record as FMF (fetal movements felt).

**Note:** CTGs are not usually performed under 26 weeks. However, if a woman is <26 weeks and reports reduced/no fetal movements, refer her to the obstetric registrar on call, clinic consultation or the PDCC, even if the FH is audible via a Sonicaid. Perceived reduced fetal movements under 26 weeks in the presence of an audible fetal heart may still require further obstetric assessment, e.g. ultrasound (AFI) or Dopplers.

4.6. Auscultation of the fetal heart (FH)

- A growing uterus and normal fetal movements indicate a fetus that is alive and well
- However, women benefit emotionally and psychologically from listening to the FH
- Therefore, offer auscultation of the FH at each visit from the time a FH can be detected using a Sonicaid
- As a guide, auscultation of the fetal heart from 16-20 weeks is recommended
- In practice, early detection of the FH is more successful on slimmer women than heavier women
- Failure to detect the FH at any gestation requires immediate referral to the obstetric registrar on call, PDCC or emergency department for viability scanning to exclude fetal demise.
Note: with regard to early auscultation, each clinician must explore the benefits and disadvantages in the light of his/her experience in conjunction with each woman's wishes and informed choice. Many experienced doctors and midwives successfully auscultate the FH with a Sonicaid from around 14 weeks. However, flexibility is encouraged for those practitioners who, given the above conditions, wish to wait longer than 16-20 weeks or choose to provide auscultation a little earlier. What is important is that women are informed reassuringly of the issues regarding early auscultation.

4.7. Abdominal palpation

It is expected all clinicians are skilled in performing abdominal inspection and palpation. See the guideline Abdominal Palpation for further information.

1. **The lie** is recorded from 30 weeks. Refer any woman found with an unstable lie from 36 weeks to the consultant.

2. **The presentation** is recorded from 33-34 weeks. A woman with breech presentation found or persisting at 36 weeks may have External Cephalic Version (ECV) discussed, offered and organised for 37 weeks in the PDCC by the obstetric Registrar or clinic Consultant. The obstetrician performing the ECV is required to confirm the booking of the ECV.

3. **Abdominal station** is recorded from 36 weeks. Its record is useful in terms of revealing a trend that may be useful for management of labour / induction.

4.8. Thrombo-embolic disease

Antenatal risk factors for thrombo-embolic disease:

- History of thrombosis
- Older women (>35)
- Grand-multiparity (>4)
- Obesity
- Heart disease
- Presence of lupus anticoagulant or other antiphospholipid antibodies
- Thrombophilia (inherited)
- Prolonged bed rest
- Pre-eclampsia

**Superficial thrombo-phlebitis**

May appear as a tender, inflamed linear area with or without varicose veins.

If you suspect superficial thrombophlebitis, the woman will require referral to the obstetric registrar on call or clinic consultant for assessment.

Treatment may require any, or a combination of:

- Stockings
- Short-term aspirin (unless close to term)
- Ointments containing anticoagulant compounds

**Deep Venous Thrombosis (DVT)**

During pregnancy – more common in left limb by a ratio of 9:1.

Classical signs (of which any may be absent):

- Calf pain
• Tenderness
• Swelling
• Warmth
• A positive Homan's sign
Any suspicion of a DVT requires immediate referral to the obstetric registrar or clinic consultant for further investigation.

Clinical assessment alone will be wrong in 30-50% of cases.

DVT can only be confirmed by Doppler Ultrasound or Venography.

Doppler Ultrasound is less invasive but is limited in assessing the pelvic veins.

**Pulmonary embolism**

Requires high index of suspicion towards:

- SOB, tachypnoea, dyspnoea
- Pleuritic chest pain
- Central chest pain
- Cough, haemoptysis
- Collapse

Any suspicion requires urgent medical attention.

### 4.9. Referral guidelines

If at any time you are unsure in your assessment, ask another more experienced colleague to perform the assessment with a woman's permission. If you are both unsure of a decisive finding, e.g. unsure of presentation at 36 weeks, it will be necessary to ask for the on-call obstetric registrar or clinic consultant to review the assessment.

- Women with obstetric related complaints, which require same day medical attention, can be referred to the obstetric registrar, the emergency department or the assessment centre
- Women with obstetric related complaints, which do not require same day medical attention, can be referred to the team obstetrician at his/her next clinic day
- Women with minor non-obstetric medical complaints can be referred to their local GP
- For women who need CTGs or hypertension assessment, they can be referred to the Pregnancy Day Care Centre (before 4.30pm) or the assessment centre (after hours) are also available for CTGs and hypertension assessment.

### 4.10 Notes on blood pressure measurement

Standardised BP measurement methods:

- To be measured, women should sit down with feet supported. Measurement should be taken after two or three minutes resting in this position. (Level iii-2 evidence)
- A standard size cuff should be used for women with an arm circumference 35cm and a large cuff used for arm circumference >33cm (Level IV evidence)
- Systolic blood pressure should be palpated at the brachial artery and the cuff inflated to 20mmHg above this level. The cuff should be deflated slowly, at approximately 2mmHg per second (Level IV evidence).
Diastolic blood pressure readings should be recorded using the Korotkov V sound. If phase V is not present, phase IV should be recorded (Level II evidence).

Hypertension is defined when systolic blood pressure is 140mmHg and/or diastolic blood pressure (Korotkov V) is 90mmHg or there is an incremental rise of 30mmHg systolic or 15Hg diastolic (Level IV evidence).

Evidence supports the use of a mercury sphygmomanometer to measure blood pressure but only an anaeroid sphygmomanometer complies with the Occupational Health and Safety Recommendations (1999). It is necessary to recalibrate anaeroid machines regularly, especially in high use situations (Level III evidence) (Three Centres Collaboration 2001 :p41).

Please note phase V is the disappearance of the Korotkov sounds. Phase IV is the muffling of the sounds (Enkin et al, 2000:p71).

1. Pregnancy-induced hypertension may occur at any time in the second half of pregnancy. It rarely occurs before 28 weeks of pregnancy, but when it does occur this early it frequently leads to pre-eclampsia with its associated high rate of perinatal morbidity and mortality. On the other hand, when pregnancy induced hypertension occurs late in the third trimester, a much more frequent occurrence, the maternal and fetal risks are much smaller. Therefore, although routine antenatal screening for hypertensive disorders before 28 weeks gestation may have a low productivity in terms of the number of positive diagnoses per visit, it has a high potential to prevent maternal and fetal morbidity and mortality (Enkin et al. 2000: p73).

2. The reduction in velocity of lower-limb flow (due to increased venous distensibility and to flow obstruction related to pressure from the gravid uterus) and the hypercoagulable state of pregnancy (due to increased concentrations of vitamin K dependent factors and to decreased fibrinolytic activity) increases the risk of thrombo-embolic disease. Consequently, pulmonary embolism joins pregnancy-induced hypertension and maternal cardiac disease as the most important non-traumatic causes of maternal death. Between 10% and 15% of women with deep venous thrombosis in their leg veins will have a pulmonary embolus (Humphrey, 1999:p85).

5. Evaluation, monitoring and reporting of compliance to this guideline

Complete the following statement compliance to this guideline will be monitored, evaluated and reported through review of incidents.

6. References


7. Legislation related to this guideline

Not applicable.

8. Appendices

*Appendix 1:* FGR Risk assessment flow chart

*Appendix 2:* Standardised SF height measurement
Guideline

Standard Antenatal Check

Please ensure that you adhere to the below disclaimer:

PGP Disclaimer Statement

The Royal Women's Hospital Clinical Guidelines present statements of 'Best Practice' based on thorough evaluation of evidence and are intended for health professionals only. For practitioners outside the Women's this material is made available in good faith as a resource for use by health professionals to draw on in developing their own protocols, guided by published medical evidence. In doing so, practitioners should themselves be familiar with the literature and make their own interpretations of it.

Whilst appreciable care has been taken in the preparation of clinical guidelines which appear on this web page, the Royal Women's Hospital provides these as a service only and does not warrant the accuracy of these guidelines. Any representation implied or expressed concerning the efficacy, appropriateness or suitability of any treatment or product is expressly negated.

In view of the possibility of human error and/or advances in medical knowledge, the Royal Women's Hospital cannot and does not warrant that the information contained in the guidelines is in every respect accurate or complete. Accordingly, the Royal Women's Hospital will not be held responsible or liable for any errors or omissions that may be found in any of the information at this site.

You are encouraged to consult other sources in order to confirm the information contained in any of the guidelines and, in the event that medical treatment is required, to take professional, expert advice from a legally qualified and appropriately experienced medical practitioner.

NOTE: Care should be taken when printing any clinical guideline from this site. Updates to these guidelines will take place as necessary. It is therefore advised that regular visits to this site will be needed to access the most current version of these guidelines.
Appendix 1

FGR Risk Assessment flowchart

FGR Risk Assessment Flow Chart

LEVEL 1

No FGR risk factors identified
More than 50% of FGR cases occur in women without identifiable risk factors.

LEVEL 2

Risk factors for FGR
- Age >35 years
- Nulliparity
- IVF singleton pregnancy
- Indigenous ethnicity
- Substance abuse: smoking, drugs
- BMI >30
- Previous late (>32 weeks) FGR/SGA and or pre-eclampsia
- PAPP A < 0.4 MoM

Antenatal complications e.g.
- Suspected FGR/SGA by SFH or USS (eg slow growth, static growth, <10th centile)
- Pre-eclampsia
- Antepartum haemorrhage
- Congenital infection

LEVEL 3

Unsuitable for SFH measurements
- BMI >40
- Large uterine fibroids

High risk of early FGR
- Previous early (<32 weeks) FGR/SGA and/or pre-eclampsia
- Previous stillbirth with FGR/SGA
- Maternal medical conditions: e.g., Antiphospholipid Syndrome
- Renal impairment
- Chronic hypertension
- Diabetes with vascular disease

Establishing the frequency and timing of ultrasound
- Review existing or newly arising risk factors
- Level A/B ACM* consultation and referral guidelines
- Frequency of ultrasound surveillance based on number of FGR risk factors, prior history and service availability (consider ultrasound of fetal size and wellbeing at 28–30 and 34–36 weeks gestation)

Serial USS 2-4 weekly from 24 weeks until birth
- Consider Uterine Artery Doppler at 20-24 weeks
- Consider low dose aspirin (100-150mg nocte) to commence prior to 16 weeks gestation
- Level B/C ACM* consultation and referral guidelines

Adapted from: Royal College of Obstetricians and Gynaecologists. The Investigation and Management of the Small-for-Gestational-Age fetus, 2013. Maternal/paternal SGA, low fruit intake and excessive daily exercise are not readily ascertainable.

*Australian College of Midwives

Feel for the fundus of the uterus.

- Palpate using the physical landmarks of the xiphisternum, umbilicus and symphysis pubis
  - Consider macrosomia, multiple pregnancy and small for gestational age.
- Between 20 and 34 weeks gestation, the height of the uterus correlates closely with measurements in centimetres. However maternal obesity can distort the accuracy of those measurements.
- Measure the fundal height with a disposable paper (or non-stretchable) tape measure with the centimeters side facing down (to avoid bias).
- Gently palpate from the lower end of the sternum and continue to palpate down the abdomen until the fundus is reached. Palpate the fundus and determine the highest point. Secure the end of the tape measure at that point with fingers.
  - If the uterus is rotated away from the midline, the highest point of the uterus will not be in the midline but will be to the left or right of the midline. Therefore, also palpate away from the midline to make sure that the highest point at which the fundus can be palpated is noted (see figure 1).
  - Do not move the fundus into the midline before marking the highest point.

Measure along the longitudinal axis of the uterus from the highest point on the fundus to the symphysis pubis without correcting to the abdominal line. (See Figure 1).
  - The tape should be in contact with the skin.
  - Measure only once.

Record the measurement in centimetres.
  - Avoid using non-specific terminology such as fundus=dates.
  - Plot on the SFH growth chart, MR/1209